Eli Lilly CEO Dave Ricks made $114 million last year, according to a new proxy statement, a rare instance of a health ...

U.S. drugmakers Johnson & Johnson and Eli Lilly increased spending on security for their top executives in 2024, citing ...

Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, ...

Eli Lilly announced Tuesday that it is selling higher-dose vials of Zepbound at lower prices in its direct-to-consumer ...

Key Takeaways Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly.The Swiss ...

It's the second year in a row that Lilly has used the Oscars as a platform to drive home a message about GLP-1-based obesity ...

Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...

In a press release, Lilly chair and CEO David A. Ricks said, “Lilly's optimism about the potential of our pipeline across ...

Eli Lilly (LLY), the maker of the blockbuster weight-loss drug Zepbound, launched a new advertising campaign on Friday ...

After scoring a long-awaited FDA approval last fall, Eli Lilly has launched a consumer-facing campaign to get the word out ...

To use the vials, people have to draw out the medicine with a syringe and inject themselves with a needle. Before launching the Zepbound vials in 2024, Eli Lilly offered the drug only in a single ...